These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39125649)

  • 1. The Expression Profiles of lncRNAs Are Associated with Neoadjuvant Chemotherapy Resistance in Locally Advanced, Luminal B-Type Breast Cancer.
    González-Woge M; Contreras-Espinosa L; García-Gordillo JA; Aguilar-Villanueva S; Bargallo-Rocha E; Cabrera-Galeana P; Vasquez-Mata T; Cervantes-López X; Vargas-Lías DS; Montiel-Manríquez R; Bautista-Hinojosa L; Rebollar-Vega R; Castro-Hernández C; Álvarez-Gómez RM; De La Rosa-Velázquez IA; Díaz-Chávez J; Jiménez-Trejo F; Arriaga-Canon C; Herrera LA
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome Analysis Identifies GATA3-AS1 as a Long Noncoding RNA Associated with Resistance to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.
    Contreras-Espinosa L; Alcaraz N; De La Rosa-Velázquez IA; Díaz-Chávez J; Cabrera-Galeana P; Rebollar-Vega R; Reynoso-Noverón N; Maldonado-Martínez HA; González-Barrios R; Montiel-Manríquez R; Bautista-Sánchez D; Castro-Hernández C; Alvarez-Gomez RM; Jiménez-Trejo F; Tapia-Rodríguez M; García-Gordillo JA; Pérez-Rosas A; Bargallo-Rocha E; Arriaga-Canon C; Herrera LA
    J Mol Diagn; 2021 Oct; 23(10):1306-1323. PubMed ID: 34358678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer.
    Arriaga-Canon C; Contreras-Espinosa L; Aguilar-Villanueva S; Bargalló-Rocha E; García-Gordillo JA; Cabrera-Galeana P; Castro-Hernández C; Jiménez-Trejo F; Herrera LA
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer.
    Miano V; Ferrero G; Reineri S; Caizzi L; Annaratone L; Ricci L; Cutrupi S; Castellano I; Cordero F; De Bortoli M
    Oncotarget; 2016 Jan; 7(3):3201-16. PubMed ID: 26621851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy.
    Zheng A; Zhang L; Song X; Jin F
    Histol Histopathol; 2020 Apr; 35(4):361-370. PubMed ID: 31638266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.
    Niknafs YS; Han S; Ma T; Speers C; Zhang C; Wilder-Romans K; Iyer MK; Pitchiaya S; Malik R; Hosono Y; Prensner JR; Poliakov A; Singhal U; Xiao L; Kregel S; Siebenaler RF; Zhao SG; Uhl M; Gawronski A; Hayes DF; Pierce LJ; Cao X; Collins C; Backofen R; Sahinalp CS; Rae JM; Chinnaiyan AM; Feng FY
    Nat Commun; 2016 Sep; 7():12791. PubMed ID: 27666543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profiles and functional prediction of long non-coding RNAs LINC01133, ZEB1-AS1 and ABHD11-AS1 in the luminal subtype of breast cancer.
    Mehrpour Layeghi S; Arabpour M; Shakoori A; Naghizadeh MM; Mansoori Y; Tavakkoly Bazzaz J; Esmaeili R
    J Transl Med; 2021 Aug; 19(1):364. PubMed ID: 34446052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis.
    Liu SQ; Zhou ZY; Dong X; Guo L; Zhang KJ
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32538432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luminal lncRNAs Regulation by ERα-Controlled Enhancers in a Ligand-Independent Manner in Breast Cancer Cells.
    Miano V; Ferrero G; Rosti V; Manitta E; Elhasnaoui J; Basile G; De Bortoli M
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
    Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
    Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
    [No Abstract]   [Full Text] [Related]  

  • 11. LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer.
    Ma Y; Bu D; Long J; Chai W; Dong J
    J Cell Physiol; 2019 Mar; 234(3):2880-2894. PubMed ID: 30203615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential roles of lncRNAs DUXAP8, LINC00963, and FOXD2-AS1 in luminal breast cancer based on expression analysis and bioinformatic approaches.
    Arabpour M; Layeghi SM; Bazzaz JT; Naghizadeh MM; Majidzadeh-A K; Shakoori A
    Hum Cell; 2021 Jul; 34(4):1227-1243. PubMed ID: 34043149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.
    Sun M; Liu X; Xia L; Chen Y; Kuang L; Gu X; Li T
    Biochem Pharmacol; 2021 Jul; 189():114285. PubMed ID: 33069665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of the long noncoding RNAs DSCAM-AS1 and MANCR is a potential diagnostic marker for breast carcinoma.
    Tahmouresi F; Razmara E; Pakravan K; Mossahebi-Mohammadi M; Rouhollah F; Montazeri M; Sarrafzadeh A; Fahimi H; Babashah S
    Biotechnol Appl Biochem; 2021 Dec; 68(6):1250-1256. PubMed ID: 33012018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer.
    Zhao Z; Guo Y; Liu Y; Sun L; Chen B; Wang C; Chen T; Wang Y; Li Y; Dong Q; Ai L; Wang R; Gu Y; Li X
    Oncogene; 2021 Jul; 40(27):4604-4614. PubMed ID: 34131286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88.
    Dong H; Wang W; Mo S; Chen R; Zou K; Han J; Zhang F; Hu J
    J Exp Clin Cancer Res; 2018 Aug; 37(1):202. PubMed ID: 30157918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
    Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
    Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling of specific long non-coding RNA signatures identifies ST8SIA6-AS1 AS a novel target for breast cancer.
    Chen Z; Huang J; Feng Y; Li Z; Jiang Y
    J Gene Med; 2021 Feb; 23(2):e3286. PubMed ID: 33037712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway.
    Zhang M; Wang Y; Jiang L; Song X; Zheng A; Gao H; Wei M; Zhao L
    J Exp Clin Cancer Res; 2021 Jan; 40(1):41. PubMed ID: 33494806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.